BiocurePharm Looks Beyond North America Via Canada IPO
Executive Summary
With a business model that sets it apart from other South Korean bioventures, BiocurePharm plans to set up manufacturing facilities in North America and worldwide with local partners, and is launching a Canadian IPO in a bid to transform into a truly multinational operation, its CEO says.
You may also be interested in...
Lucentis Biosimilar To Be Sold To Emerging Markets By Xbrane Biopharma
Stockholm-based Xbrane Biopharma plans to be the first to sell a biosimilar version of Lucentis in Iran as part of its strategy to leverage patent gaps in emerging markets for high-priced drugs.
AI Healthcare, Medical Devices Shine In Korea Q1 Financings
After the financing draught suffered by Korean bioventures in 2023, it now seems the VC market is poised for a recovery as investors shift attention again to the healthcare sector, with a spotlight on AI-based solutions and device firms.
Window Of Opportunity: Korea Unveils Cutting-Edge Bio Initiative
South Korea is moving forward with plan to set up a Boston-type biotech cluster in Osong as part of a broader initiative unveiled by President Yoon, while the biopharma industry is calling for rapid process, exceptional support.